Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Blood (2023) 141 (19): 2307–2315.

https://doi.org/10.1182/blood.2022018893

Published: 2023

Includes: Supplemental data

Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes

Arushi Khurana, Megumi Bailey, Madiha Iqbal, Radhika Bansal, Catherine J. Lee, Bradley Hunter, Matthew A. Lunning, Samantha Jaglowski, Michael D. Jain, Saurabh Dahiya, Veronika Bachanova, Umar Farooq, Sairah Ahmed, Brian T. Hill, Javier L. Munoz, Krish Patel, Olalekan O. Oluwole, Yi Lin

Blood (2022) 140 (Supplement 1): 4657–4660.

https://doi.org/10.1182/blood-2022-170486

Published: 2022

Journal Articles

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Blood (2022) 140 (Supplement 1): 4636–4638.

https://doi.org/10.1182/blood-2022-169452

Published: 2022

Journal Articles

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Blood (2022) 140 (Supplement 1): 3839–3841.

https://doi.org/10.1182/blood-2022-157105

Published: 2022

Journal Articles

Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma

Blood (2022) 140 (Supplement 1): 6489–6491.

https://doi.org/10.1182/blood-2022-167633

Published: 2022

Journal Articles

Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry

David A. Bond, Jason T. Romancik, Jeffrey M. Switchenko, Brielle Berkowitz, Jonathan R Day, Umar Farooq, Sabarish Ayyappan, Katelin Baird, Michelle L. Churchman, Andrew M. Evens, Bijal D. Shah, Craig A. Portell, Kami J. Maddocks, Brian K. Link, Jonathon B. Cohen, Deborah M. Stephens

Blood (2022) 140 (Supplement 1): 6509–6511.

https://doi.org/10.1182/blood-2022-160306

Published: 2022

Journal Articles

Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting

Blood (2022) 140 (Supplement 1): 6517–6519.

https://doi.org/10.1182/blood-2022-165419

Published: 2022

Journal Articles

Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era

Sanjal H Desai, Raphael Mwangi, Yucai Wang, Umar Farooq, Eric Mou, Andrew L. Feldman, Sergei Syrbu, Susan L. Slager, Grzegorz S. Nowakowski, Matthew J. Maurer, Neil E. Kay, Thomas M. Habermann, Brian K. Link, Carrie A. Thompson, James R. Cerhan

Blood (2022) 140 (Supplement 1): 1934–1936.

https://doi.org/10.1182/blood-2022-165207

Published: 2022

Journal Articles

Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis

Arushi Khurana, Raphael Mwangi, Loretta J. Nastoupil, Patrick M. Reagan, Umar Farooq, Jason T. Romancik, Timothy J. McDonnell, Shaun M Riska, Izidore S. Lossos, Brad S. Kahl, Peter Martin, Thomas E. Witzig, James R. Cerhan, Christopher R. Flowers, Matthew J. Maurer, Grzegorz S. Nowakowski

Blood (2022) 140 (Supplement 1): 2056–2058.

https://doi.org/10.1182/blood-2022-169433

Published: 2022

Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

Blood (2022) 140 (Supplement 1): 10399–10401.

https://doi.org/10.1182/blood-2022-156117

Published: 2022

Journal Articles

Molecular Landscape of Primary Refractory DLBCL

Blood (2022) 140 (Supplement 1): 9221–9223.

https://doi.org/10.1182/blood-2022-156497

Published: 2022

Journal Articles

Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Rashmi Khanal, Jennifer N. Saultz, Umar Farooq, Sunita Nathan, Amitkumar Mehta, Ayad Hamdan, Lawrence E. Morris, Jr., Houston Holmes, Lauren C. Pinter-Brown, John K.C. Lim, Amanda Conerty, Heather Raymon, Peter Flynn, Anita G. Seto, Joseph J. Maly

Blood (2022) 140 (Supplement 1): 12742–12743.

https://doi.org/10.1182/blood-2022-159282

Published: 2022

Journal Articles

Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

Amitkumar Mehta, Umar Farooq, Andy Chen, Joseph P. McGuirk, Thomas Ly, Lilly Wong, Sarah Cooley, Bahram Valamehr, Rebecca Elstrom, Yu-Waye Chu, Jae H. Park

Blood (2022) 140 (Supplement 1): 4577–4578.

https://doi.org/10.1182/blood-2022-167194

Published: 2022

Journal Articles

A Multi-Institution Analysis of Relapsed Lymphoma Occurring during Pregnancy Including Pharmacokinetics with Antenatal Checkpoint Inhibitor Therapy

Blood (2021) 138 (Supplement 1): 2457.

https://doi.org/10.1182/blood-2021-149220

Published: 2021

Journal Articles

Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy

Veronika Bachanova, Livia Hegerova, Qing Cao, Murali Janakiram, Joseph Maakaron, Sabarish Ayyappan, Daniel J. Weisdorf, Jaroslav Zak, Umar Farooq, Vaishalee P. Kenkre

Blood (2021) 138 (Supplement 1): 230.

https://doi.org/10.1182/blood-2021-149675

Published: 2021

Journal Articles

Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era

Yucai Wang, Melissa C. Larson, Alessia Castellino, Matthew J. Maurer, Andrew L. Feldman, Sergei Syrbu, Brian K. Link, Umar Farooq, David J. Inwards, Jonas Paludo, Thomas E. Witzig, Thomas M. Habermann, James R. Cerhan, Grzegorz S. Nowakowski

Blood (2021) 138 (Supplement 1): 2429.

https://doi.org/10.1182/blood-2021-147538

Published: 2021

Journal Articles

Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Xavier Andrade-Gonzalez, Raphael Mwangi, Jithma P. Abeykoon, Paul J. Hampel, Saurabh Zanwar, Betsy Laplant, Gita Thanarajasingam, Umar Farooq, Matthew J. Maurer, Thomas E. Witzig, Thomas M. Habermann, Jose C. Villasboas, Anne J. Novak

Blood (2021) 138 (Supplement 1): 1439.

https://doi.org/10.1182/blood-2021-151973

Published: 2021

Journal Articles

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2.

https://doi.org/10.1182/blood-2021-148039

Published: 2021

Journal Articles

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Blood (2021) 138 (Supplement 1): 1764.

https://doi.org/10.1182/blood-2021-148078

Published: 2021

Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

Blood (2021) 138 (Supplement 1): 2832.

https://doi.org/10.1182/blood-2021-147403

Published: 2021

NARROW

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma

Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry

Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting

Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era

Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

Molecular Landscape of Primary Refractory DLBCL

Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

A Multi-Institution Analysis of Relapsed Lymphoma Occurring during Pregnancy Including Pharmacokinetics with Antenatal Checkpoint Inhibitor Therapy

Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy

Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era

Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only